These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 8921822

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G.
    Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E, Camanni F.
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B, Nesher Y, Barziliai S.
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [Abstract] [Full Text] [Related]

  • 11. Quinagolide in the management of prolactinoma.
    Schultz PN, Ginsberg L, McCutcheon IE, Samaan N, Leavens M, Gagel RF.
    Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.
    Vilar L, Burke CW.
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):821-6. PubMed ID: 7889620
    [Abstract] [Full Text] [Related]

  • 18. Prolactinomas and resistance to dopamine agonists.
    Brue T, Pellegrini I, Priou A, Morange I, Jaquet P.
    Horm Res; 1992 Dec; 38(1-2):84-9. PubMed ID: 1306523
    [Abstract] [Full Text] [Related]

  • 19. Resistance to bromocriptine in prolactinomas.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A.
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [Abstract] [Full Text] [Related]

  • 20. Prolactinomas and pregnancy.
    Bronstein MD.
    Pituitary; 2005 Sep; 8(1):31-8. PubMed ID: 16411066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.